SCHEMBL17125232

SCHEMBL17125232

Cc1cc(F)cc(C(C)C)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.39
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
FKBP1A P62942 1/20 0.35
CYP3A4 P08684 1/20 0.34
CHRM1 P11229 1/20 0.34
ALOX15 P16050 1/20 0.34
MAOA P21397 1/20 0.34
TBXA2R P21731 1/20 0.34
ADRA1A P35348 1/20 0.34
HTR2B P41595 1/20 0.34
RAPGEF4 Q8WZA2 3/20 0.34
KCNH2 Q12809 1/20 0.32
PSEN1 P49768 1/20 0.31
PSEN2 P49810 1/20 0.31
APH1B Q8WW43 1/20 0.31
NCSTN Q92542 1/20 0.31
APH1A Q96BI3 1/20 0.31
PSENEN Q9NZ42 1/20 0.31
FFAR4 Q5NUL3 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26203728 0.86 GABRA1 (0.41) LMNAGABRA1GABRB1CYP3A4KCNH2
SCHEMBL21316937 0.80 GABRA1 (0.37) LMNAGABRA1GABRB1KCNH2PSEN1
SCHEMBL2839922 0.78 CYP3A4 (0.52) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL9945897 0.77 LMNA (0.33) LMNACHRM1ADRA1AHTR2B
SCHEMBL12329570 0.77 LMNA (0.33) LMNACHRM1ADRA1AHTR2B
SCHEMBL17125221 0.77 LMNA (0.42) LMNAGABRA1GABRB1FKBP1ACYP3A4
SCHEMBL31376150 0.77 GABRA1 (0.34) LMNAGABRA1GABRB1KCNH2PSEN1
SCHEMBL9618707 0.76 GABRA1 (0.43) LMNAGABRA1GABRB1FKBP1ACYP3A4
SCHEMBL13377468 0.76 LMNA (0.32) LMNACHRM1ADRA1AHTR2B
SCHEMBL15934963 0.75 PDE2A (0.41) LMNAGABRA1GABRB1FKBP1ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2906542-B1 SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS MERCK SHARP & DOHME (US) 2019-08-07 EP disclosed
US-9708270-B2 Substituted spiropiperidinyl compounds useful as GPR120 agonists MERCK SHARP & DOHME CORP. (US) 2017-07-18 US disclosed
US-9708270-B2 Substituted spiropiperidinyl compounds useful as GPR120 agonists MERCK SHARP & DOHME CORP. (US) 2017-07-18 US disclosed
US-20150274672-A1 SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS MERCK SHARP & DOHME CORP. (US) 2015-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150274672-A1 SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS GPR119, GPR180, GPR88 LMNA 3442/4885GABRA1 491/4885GABRB1 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.